on SENSORION (EPA:ALSEN)
Louis J. Arcudi III appointed Chief Financial Officer of Sensorion
On October 7, 2026, Sensorion, a biotechnology company focused on hearing therapies, announced the appointment of Louis J. Arcudi III as Chief Financial Officer. Based in Boston, Arcudi succeeds Laurene Danon, who will continue to advise the company to facilitate the transition.
Arcudi brings extensive financial experience, having previously held key positions at Amolyt Pharma and Millendo Therapeutics. His expertise will be invaluable to the development of the SENS-601 treatment, currently in Phase I/II clinical trials.
Laurene Danon, in her position since 2023, has played a crucial role in fundraising, notably one of 60 million euros in 2026, strengthening Sensorion's financial position.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news